Viridian Therapeutics, Inc. (VRDN) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $16.37: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 1.71; Below-average business quality.
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under Priority Review with PDUFA June 30, 2026) and elegrobart (SC IGF-1R, Phase 3 REVEAL-1/2 results expected Q1/Q2 2026) for thyroid eye disease, plus FcRn inhibitors... Read more
Sell if holding. Engine safety override at $16.37: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 1.71; Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Viridian Therapeutics, Inc.
Latest news
- NEWS Viridian Therapeutics Strikes Commercial Manufacturing Services Agreement With WuXi Biologics To Produce, Supply Veligro — benzinga May 26, 2026 positive
- NEWS Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $26 — benzinga May 15, 2026 positive
- NEWS Reported Earlier, Viridian Therapeutics Prices Upsized $350M Concurrent Offerings Of $225M 1.75% Convertible Notes Due 2 — benzinga May 7, 2026 positive
- NEWS RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $34 — benzinga May 6, 2026 positive
- NEWS 12 Health Care Stocks Moving In Tuesday's Intraday Session — benzinga May 5, 2026 neutral
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.37: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 8.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 1.71; Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $15.32. Score 5.3/10, moderate confidence.
Take-profit target: $30.54 (+85.4% upside). Prior stop was $15.32. Stop-loss: $15.32.
Quality below floor (1.6 < 4.0).
Viridian Therapeutics, Inc. trades at a P/E of N/A (forward -6.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
23 analysts cover VRDN with a consensus score of 4.3/5. Average price target: $34.
What does Viridian Therapeutics, Inc. do?Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under...
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing veligrotug (IV IGF-1R, BLA under Priority Review with PDUFA June 30, 2026) and elegrobart (SC IGF-1R, Phase 3 REVEAL-1/2 results expected Q1/Q2 2026) for thyroid eye disease, plus FcRn inhibitors VRDN-006 and VRDN-008 for autoimmune disorders. No products approved; $874.7M cash as of December 31, 2025.